Extended Data Fig. 7: Depth and duration of response by histology subgroup. | Nature Medicine

Extended Data Fig. 7: Depth and duration of response by histology subgroup.

From: First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial

Extended Data Fig. 7

a, b, waterfall plot depicting the maximum change from baseline in target lesion size in patients with non-squamous carcinoma (a) and squamous carcinoma (b); c, d, spider plots showing the percentage change from baseline in the sum of the longest diameters (SLD) of target lesions over time in patients with non-squamous carcinoma (c) and squamous carcinoma (d). Each line represents an individual patient; timepoints (x-axis) show scheduled assessments; the y-axis indicates SLD change (%). The end of each line is marked with a square to indicate treatment discontinuation (last assessment before stopping treatment for any reason) or a triangle to indicate treatment ongoing (patient still receiving therapy at the data cutoff).

Back to article page